Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Comorbidity and mortality results from a randomized prostate cancer screening trial.

Crawford ED, Grubb R 3rd, Black A, Andriole GL Jr, Chen MH, Izmirlian G, Berg CD, D'Amico AV.

J Clin Oncol. 2011 Feb 1;29(4):355-61. doi: 10.1200/JCO.2010.30.5979. Epub 2010 Nov 1.

2.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.

J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.

3.

Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.

Aizer AA, Chen MH, Hattangadi J, D'Amico AV.

BJU Int. 2014 Jan;113(1):43-50. doi: 10.1111/j.1464-410X.2012.11789.x. Epub 2013 Mar 8.

4.

Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.

Wo JY, Chen MH, Nguyen PL, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV.

J Clin Oncol. 2009 Dec 10;27(35):6000-5. doi: 10.1200/JCO.2009.23.6067. Epub 2009 Oct 26.

PMID:
19858385
5.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
6.

Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):147-52. doi: 10.1016/j.ijrobp.2009.04.085. Epub 2009 Sep 8.

PMID:
19744800
7.

Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.

Hattangadi JA, Chen MH, D'Amico AV.

BJU Int. 2012 Dec;110(11):1636-41. doi: 10.1111/j.1464-410X.2012.11354.x. Epub 2012 Jul 3.

8.

Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.

Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.

Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17.

PMID:
21601352
9.

Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).

Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV.

BJU Int. 2012 Oct;110(7):973-9. doi: 10.1111/j.1464-410X.2012.11470.x.

11.

Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.

12.

The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml.

Pashtan I, Chen MH, D'Amico AV.

Cancer Epidemiol. 2014 Oct;38(5):613-8. doi: 10.1016/j.canep.2014.07.007. Epub 2014 Aug 19.

PMID:
25164550
13.

Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.

Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.

Urology. 2008 Jan;71(1):136-40. doi: 10.1016/j.urology.2007.08.028.

PMID:
18242382
14.

Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.

Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, Kirkels WJ, Otto SJ, van der Kwast TH, de Koning HJ, Schröder FH; ERSPC Rotterdam Study Group.

Eur Urol. 2013 Oct;64(4):530-9. doi: 10.1016/j.eururo.2013.05.030. Epub 2013 May 25.

PMID:
23759326
15.

Prostate cancer and prostate-specific antigen (PSA) screening in Austria.

Vutuc C, Schernhammer ES, Haidinger G, Waldhör T.

Wien Klin Wochenschr. 2005 Jul;117(13-14):457-61.

PMID:
16091872
17.

Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.

Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J.

Eur Urol. 2015 Sep;68(3):354-60. doi: 10.1016/j.eururo.2014.12.006. Epub 2014 Dec 31.

PMID:
25556937
18.

Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.

Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV.

J Clin Oncol. 2005 Sep 20;23(27):6556-60.

PMID:
16170163
19.

Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):e209-15. doi: 10.1016/j.ijrobp.2012.11.039. Epub 2013 Jan 16.

PMID:
23332383
20.

Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.

Lee BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Feb;67(2):204-9. doi: 10.1016/j.eururo.2014.09.017. Epub 2014 Oct 5.

PMID:
25294696

Supplemental Content

Support Center